source
- Servier acquires Edgewise's muscular dystrophy assets for $1.55 billionServier announced it will purchase the muscular dystrophy business from Edgewise Therapeutics. The deal involves an upfront payment of $1.55 billion, giving the French company rights to Edgewise's…
- AstraZeneca reports promising triplet therapy results in liver cancer subgroupAstraZeneca presented new data at ASCO 2026 showing that a regimen combining a targeted agent with two immunotherapies produced clinical benefit in a subset of liver cancer patients. The study eva…